AEON Biopharma Inc is a biopharmaceutical company focused on the development of ABP-450 (prabotulinumtoxinA), a biosimilar to Botox (onabotulinumtoxinA), for therapeutic indications... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
AEON is expected to report earnings to fall 95.25% to -13 cents per share on November 18
Q3'26
Est.
$-0.14
Q4'25
Missed
by $2.64
Q3'25
Missed
by $0.07
Q2'25
Missed
by $0.29
Q1'25
Beat
by $2.57
The last earnings report on March 30 showed earnings per share of -288 cents, missing the estimate of -23 cents. With 1.72M shares outstanding, the current market capitalization sits at 9.58M.